Nanoparticle-Mediated Wild-Type p53 Gene Delivery Results in Sustained Antiproliferative Activity in Breast Cancer Cells
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Gene expression with nonviral vectors is usually transient and lasts for only a few days. Therefore, repeated injection of the expression vector is required to maintain a therapeutic protein concentration in the target tissue. Biodegradable nanoparticles (approximately 200 nm diameter) formulated using a biocompatible polymer, poly(D,L-lactide-co-glycolide) (PLGA), have the potential for sustained gene delivery. Our hypothesis is that nanoparticle-mediated gene delivery would result in sustained gene expression, and hence better efficacy with a therapeutic gene. In this study, we have determined the antiproliferative activity of wild-type (wt) p53 gene-loaded nanoparticles in a breast cancer cell line. Nanoparticles containing plasmid DNA were formulated using a multiple-emulsion-solvent evaporation technique. To understand the mechanism of sustained gene expression with nanoparticles, we monitored the intracellular trafficking of both the nanoparticles and the nanoparticle-entrapped DNA, and also determined p53 mRNA levels over a period of time. Cells transfected with wt-p53 DNA-loaded nanoparticles demonstrated a sustained and significantly greater antiproliferative effect than those with naked wt-p53 DNA or wt-p53 DNA complexed with a commercially available transfecting agent (Lipofectamine). Cells transfected with wt-p53 DNA-loaded nanoparticles demonstrated sustained p53 mRNA levels compared to cells which were transfected with naked wt-p53 DNA or the wt-p53 DNA-Lipofectamine complex, thus explaining the sustained antiproliferative activity of nanoparticles. Studies with fluorescently labeled DNA using confocal microscopy and quantitative analyses using a microplate reader demonstrated sustained intracellular localization of DNA with nanoparticles, suggesting the slow release of DNA from nanoparticles localized inside the cells. Cells which were transfected with naked DNA demonstrated transient intracellular DNA retention. In conclusion, nanoparticle-mediated wt-p53 gene delivery results in sustained antiproliferative activity, which could be therapeutically beneficial in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy - promises, problems and prospects
Verma, I. M., & Somia, N. (1997) · Nature · doi:10.1038/38410 · Cited by 1,681
Cited by
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
The present and future of nanotechnology in human health care
Sahoo, S. K., Parveen, S., & Panda, J. J. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2006.11.008 · Cited by 905
Nanoparticles in cellular drug delivery
Faraji, A. H., & Wipf, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.043 · Cited by 903
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0141 · Cited by 801
Synthesis and characterization of PLGA nanoparticles
Astete, C. E., & Sabliov, C. M. (2006) · Journal of Biomaterials Science, Polymer Edition · doi:10.1163/156856206775997322 · Cited by 776
Multifunctional nanostructured PLA materials for packaging and tissue engineering
Armentano, I., Bitinis, N., Fortunati, E., Mattioli, S., Rescignano, N., Verdejo, R., Lopez-Manchado, M. A., & Kenny, J. M. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.05.010 · Cited by 645
Safe Nanoparticles: Are We There Yet?
Najahi-Missaoui, W., Arnold, R. D., & Cummings, B. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010385 · Cited by 581
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Nanoparticles: Health Effects—Pros and Cons
Gwinn, M. R., & Vallyathan, V. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8871 · Cited by 571
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
“Breast cancer cells (MDA-MB-435S) transfected with wt-p53 plasmid DNA loaded NPs showed significantly higher and more sustained (7 days) intracellular DNA levels as opposed to transfection with naked DNA and DNA-LipofectamineTM complex [46].”
BackgroundSelf-citationSahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102487 · Cited by 487
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340
Self-citationTargeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Acharya, S., Dilnawaz, F., & Sahoo, S. K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.008 · Cited by 333
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery
Parveen, S., & Sahoo, S. K. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.023 · Cited by 302
Polymeric nanoparticles for siRNA delivery and gene silencing
Patil, Y., & Panyam, J. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.039 · Cited by 270
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6966-1 · Cited by 264
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Chang, S. C., Gopal, P., Lim, S., Wei, X., Chandramohan, A., Mangadu, R., Smith, J., Ng, S., Gindy, M., Phan, U., et al. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.10.005 · Cited by 31
Metadata
- Authors
- Prabha, S., & Labhasetwar, V.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2004-03-31
- Volume
- 1
- Issue
- 3
- Pages
- 211-219
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2089633391
- Cited by
- 127
- References
- 1
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.